132 related articles for article (PubMed ID: 35597299)
1. Mutations in DNA binding domain of p53 impede RSL1D1-p53 interaction to escape from degradation in human colorectal cancer cells.
Ding L; Zhao C; Xu Y; Zhang Z; Nie Y; Liao K; Chen Y; Tu B; Zhang X
Exp Cell Res; 2022 Aug; 417(1):113211. PubMed ID: 35597299
[TBL] [Abstract][Full Text] [Related]
2. Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells.
Ding L; Zhang Z; Zhao C; Chen L; Chen Z; Zhang J; Liu Y; Nie Y; He Y; Liao K; Zhang X
J Exp Clin Cancer Res; 2021 Aug; 40(1):245. PubMed ID: 34362424
[TBL] [Abstract][Full Text] [Related]
3. RSL1D1 promotes the progression of colorectal cancer through RAN-mediated autophagy suppression.
Liu X; Chen J; Long X; Lan J; Liu X; Zhou M; Zhang S; Zhou J
Cell Death Dis; 2022 Jan; 13(1):43. PubMed ID: 35013134
[TBL] [Abstract][Full Text] [Related]
4. P53-R273H mutation enhances colorectal cancer stemness through regulating specific lncRNAs.
Zhao Y; Li Y; Sheng J; Wu F; Li K; Huang R; Wang X; Jiao T; Guan X; Lu Y; Chen X; Luo Z; Zhou Y; Hu H; Liu W; Du B; Miao S; Cai J; Wang L; Zhao H; Ying J; Bi X; Song W
J Exp Clin Cancer Res; 2019 Aug; 38(1):379. PubMed ID: 31455383
[TBL] [Abstract][Full Text] [Related]
5. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
Li L; Li X; Tang Y; Lao Z; Lei J; Wei G
Phys Chem Chem Phys; 2020 May; 22(17):9225-9232. PubMed ID: 32307496
[TBL] [Abstract][Full Text] [Related]
6. Butein inhibits cancer cell growth by rescuing the wild-type thermal stability of mutant p53.
Song B; Wang J; Ren Y; Su Y; Geng X; Yang F; Wang H; Zhang J
Biomed Pharmacother; 2023 Jul; 163():114773. PubMed ID: 37156116
[TBL] [Abstract][Full Text] [Related]
7. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
Demma M; Maxwell E; Ramos R; Liang L; Li C; Hesk D; Rossman R; Mallams A; Doll R; Liu M; Seidel-Dugan C; Bishop WR; Dasmahapatra B
J Biol Chem; 2010 Apr; 285(14):10198-212. PubMed ID: 20124408
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death 11 modulates but not entirely relies on p53-HDM2 loop to facilitate G2/M transition in colorectal cancer cells.
Ding L; Xu Y; Xu L; Zhao C; Zhang Z; Zhang J; Liao K; Chen Y; Li J; Mei X; Zhang X
Oncogenesis; 2023 Dec; 12(1):57. PubMed ID: 38062028
[TBL] [Abstract][Full Text] [Related]
9. Characterization of functional domains necessary for mutant p53 gain of function.
Yan W; Chen X
J Biol Chem; 2010 May; 285(19):14229-38. PubMed ID: 20212049
[TBL] [Abstract][Full Text] [Related]
10. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
11. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
Wu X; Lu Y; Qin X
J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
Dong P; Xu Z; Jia N; Li D; Feng Y
Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
[TBL] [Abstract][Full Text] [Related]
15. A common gain of function of p53 cancer mutants in inducing genetic instability.
Liu DP; Song H; Xu Y
Oncogene; 2010 Feb; 29(7):949-56. PubMed ID: 19881536
[TBL] [Abstract][Full Text] [Related]
16. Butyrate supplementation regulates expression of chromosome segregation 1‑like protein to reverse the genetic distortion caused by p53 mutations in colorectal cancer.
Chang CC; Kao WY; Liu CY; Su HH; Kan YA; Lin PY; Ku WC; Chang KW; Yang RN; Huang CJ
Int J Oncol; 2022 Jun; 60(6):. PubMed ID: 35417036
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.
Kalo E; Kogan-Sakin I; Solomon H; Bar-Nathan E; Shay M; Shetzer Y; Dekel E; Goldfinger N; Buganim Y; Stambolsky P; Goldstein I; Madar S; Rotter V
J Cell Sci; 2012 Nov; 125(Pt 22):5578-86. PubMed ID: 22899716
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
[TBL] [Abstract][Full Text] [Related]
19. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
[TBL] [Abstract][Full Text] [Related]
20. Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.
Brázdová M; Navrátilová L; Tichý V; Němcová K; Lexa M; Hrstka R; Pečinka P; Adámik M; Vojtesek B; Paleček E; Deppert W; Fojta M
PLoS One; 2013; 8(3):e59567. PubMed ID: 23555710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
